ABOS: the balance sheet

MyFinsight

For the quarter ending 2026-03-31, ABOS has $133,629K in assets. $46,153K in debts. $51,796K in cash and cash equivalents.

Balance Sheets	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Cash and cash equivalents	51,796	53,989	46,832	36,810
Marketable securities, short-term	76,602	62,876	79,777	106,559
Prepaid expenses and other current assets	4,696	5,387	5,544	5,035
Total current assets	133,094	122,252	132,153	148,404
Marketable securities, long-term	-	0	9,443	22,797
Restricted cash	231	231	232	232
Other assets, long-term	304	350	393	464
Total assets	133,629	122,833	142,221	171,897

Accounts payable	1,655	554	682	2,103
Accrued clinical trial expenses	8,183	10,616	9,884	11,108
Accrued expenses and other current liabilities	5,268	10,072	7,792	11,650
Debt, short-term	14,123	8,765	3,598	-
Total current liabilities	29,229	30,007	21,956	24,861
Other liabilities, long-term	-	0	39	77
Debt, long-term	16,924	22,396	27,053	29,882
Total liabilities	46,153	52,403	49,048	54,820
Common stock, 0.0001 par value 300,000,000 shares authorized as of march31, 2026 and december31, 2025 72,227,580 and 60,575,369 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively	7	6	6	6
Additional paid-in capital	554,647	516,803	514,382	511,921
Accumulated deficit	-467,199	-446,462	-421,324	-394,873
Accumulated other comprehensive income	21	83	109	23
Total stockholders equity	87,476	70,430	93,173	117,077
Total liabilities and stockholders equity	133,629	122,833	142,221	171,897

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.